iiinova — where your digital self keeps evolving

Nick Webb

@profnickwebb.bsky.social

497 followers 769 following 2 posts

Paediatric nephrologist VP Medical Affairs / Clinical Development at Sobi Basel 🇨🇭 Anti-complement therapy for rare kidney disease 🏃 and ⛷️and COYS

Posts Replies Media

Reposted by Nick Webb

Sobi Nephrology @sobi-nephrology.bsky.social · 06/06/2025

📣Excited to share with the #nephrology community the latest updates in #C3G and primary #ICMPGN clinical trials at #ERA25. If you are a healthcare professional, do not miss the late breaking session: Innovative Kidney Trials at ⏲️15:00 at the Square #nephrology #kidneydisease

041

Reposted by Nick Webb

Sobi Nephrology @sobi-nephrology.bsky.social · 04/06/2025

We are excited to be at #ERA25 in sunny Vienna🔅. If you are a healthcare professional join us at booth X3.110 to meet the #Sobi team and learn more about #C3G #IC-MPGN #complement #Rare_Sobi #Sobi_nephrology

061

Reposted by Nick Webb

Sobi Nephrology @sobi-nephrology.bsky.social · 04/06/2025

📣 Save the date! Our symposium at #ERA25, where we will explore the power of #complement inhibition in #C3G and primary #ICMPGN, join Prof Marina Vivarelli, Prof. Matthew Pickering and Prof. Fadi Fakhouri on 🗓️ June 6, 🕙 10:00-11:00 (CEST) in Hall B

051

Reposted by Nick Webb

ISNkidneycare @theisn.org · 04/04/2025

Findings on the Sparsentan study: A New Dawn for IgA Nephropathy. ⬇️ Download the visual abstract: www.theisn.org/wp-co... 📽️ Watch the industry webinar: academy.theisn.org/p... Supported by @travererare.bsky.social

053

Reposted by Nick Webb

Shilpa Jesudason @shilpajesudason.bsky.social · 16/02/2025

@kidneydoc101.bsky.social is the President Elect of the @theisn.org ! Honoured to call this exceptional woman and Leader my friend and colleague, and look forward to her vibrant contributions to #Kidneyhealth

2183

Reposted by Nick Webb

Michelle Rheault, MD @rheaultm.bsky.social · 12/02/2025

Sparsentan for FSGS isn’t dead yet… ir.travere.com/news-release...

ir.travere.com

023

Reposted by Nick Webb

Milagros Flores @dramiliflores.bsky.social · 07/02/2025

Join the @theisn.org ! 🌍 We continue our mission in advancing kidney care! The SoMe team is enjoying the #ISNWCN #MedSky #NephSky

0167

Reposted by Nick Webb

Joel Topf @kidneyboy.bsky.social · 07/02/2025

Omg omg omg www.kidneyfund.org/article/fda-...

kidneyfund.org

FDA greenlights first clinical trials for genetically modified pig kidney transplants in humans

Two companies have received FDA approval to conduct clinical trials transplanting genetically modified pig kidneys into patients with kidney failure

59218

Reposted by Nick Webb

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 17/11/2024

The 2024 USRDS report is out (a few weeks ago actually) usrds-adr.niddk.nih.gov/2024 It’s a treasure trove of data for nephrology nerds, aka all of #NephSky So, short 🧶 on ESRD incidence/prevalence

usrds-adr.niddk.nih.gov

Annual Data Report | USRDS

Unites States Renal Data System Annual Data Report

27420

Nick Webb @profnickwebb.bsky.social · 16/11/2024

Fascinating - didn’t learn this at medical school!

040

Nick Webb @profnickwebb.bsky.social · 16/11/2024

This is so very helpful - thanks for putting it all together

030

Reposted by Nick Webb

༺DailyHemo༻ @dailyhemo.bsky.social · 14/08/2024

The phase 3 VALIANT trial has been evaluating the drug, pegcetacoplan, in patients with C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). pmlive.com/pharma_news/... #kidneyhealth

pmlive.com

Sobi and Apellis’ pegcetacoplan shows promise in phase 3 rare kidney disease study - PMLiVE

There are currently no treatments that target the underlying cause of C3G or IC-MPGN

092

Reposted by Nick Webb

Jasmine Sethi @jasminenephro.bsky.social · 14/11/2024

🫘🧬Complement testing in patients with C3 Glomerulopathy doi.org/10.1093/ndt/... @ndt journal

1155